ArticleWorld journal of microbiology & biotechnology2025
Revisiting the endo and exo mode of action of dextran hydrolyzing enzymes, and their significance for Streptococcus mutans biofilm eradication.
Article in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enzymatic tools for the treatment of caries-associated biofilms: Investigating the enzymes of a putative polysaccharide utilization locus from Prevotella melaninogenica and their application against Streptococcus mutans biofilm.World journal of microbiology & biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Streptococcus mutans is a major microorganism causing dental caries. The mechanism by which caries arises involve the production of extracellular polysaccharides by S. mutans, which further assemble into a biofilm. Several strategies, including enzymatic deconstruction of the carbohydrate portion of the biofilm, can potentially be used to combat the formation of oral biofilms. We set out to heterologously produce two different S. mutans dextranases: DexA and DexB, from glycoside hydrolase families 66 (GH66) and 13 (GH13), respectively, and to study their capacity to degrade S. mutans biofilms. The S. mutans enzymes were recombinantly produced in E. coli, purified, biochemically characterized and applied to hydrolyze mature S. mutans biofilms as well as to prevent the biofilm formation. Two recombinant S. mutans dextranases have different modes of action: GH66 DexA is an endo-acting enzyme whereas DexB is an exo-acting enzyme. DexA is more thermostable than DexB, with the maximum activity observed at 40 °C and pH 5. When applied separately, DexA is capable of degrading S. mutans biofilms and displays synergism with α-1,3-glucanase, thereby further enhancing biofilm removal. Although DexB displayed a reduced potential to remove oral biofilms, when coupled with carbohydrate esterase from CE4 family and α-1,3-glucanase, biofilm removal above 50% was achieved. In addition to biofilm degradation, DexA inhibited biofilm formation, which was not observed for DexB. The results of this study can aid in the development of novel enzyme-based oral hygiene products.
Indexed as
Identifiers
41474477What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.